DEA Schedule III Decision Could Trigger a Cannabis M&A Wave

The DEA Just Started the Clock on Cannabis M&A

The DEA just published the corrected transcript of its 11-day rescheduling hearing. All 2,533 pages. Posted August 25 — a day ahead of Chief ALJ Derek Julius's August 26 deadline. That detail matters more than the pages. Julius sets dates in writing, then beats them. Briefs closed August 17. The correction order landed August 20. The record went public on the 25th. Chambers is moving. And the record tilts one way. The opposition kept conceding the government's case. SAM's own Harvard expert was asked if marijuana meets the Schedule III criteria. She said yes. The states' law-enforcement closer admitted regulated cannabis helps cops. That came on cross. DEA's final brief counted 30,000 doctors and six million patients across 43 states and territories. Then it asked Julius to hurry. No law puts a clock on his call. Everything about this docket says sooner, not later.

What an Expedited Schedule III Actually Does

Keep the sequence straight. Most coverage doesn't. Trump's December 18 order demanded speed. In April, DOJ split the issue in two. Acting Attorney General Todd Blanche used separate authority to place FDA-approved marijuana products and marijuana covered by qualifying state medical licenses into Schedule III, effective April 28. That part is already law. The broader rulemaking now before Julius addresses the remainder of marijuana covered by the CSA. Adult-use included. Julius recommends. Administrator Cole signs the final rule. The Federal Register prints it. Then the whole industry lives under Schedule III, not just the medical slice.

The 280E Segment: Where the Money Lands

Section 280E only touches Schedule I and II drugs. Medical operators have deducted rent and payroll like normal businesses since April. A full ruling extends that to every dollar of licensed revenue. Effective tax rates fall from the 60s toward the low 20s. Our estimate: $350 million-plus in fresh annual free cash flow across the top five operators alone.

Here's what the cheerleaders miss. That dividend isn't fungible. The sector splits into castes. Owners keep every dollar. Green Thumb $GTBIF owns most of its boxes. Glass House $GLAS owns its greenhouses. Renters pre-sold part of the windfall to their landlord years ago. Cresco $CRLBF is the textbook. It sold Joliet and Kankakee to IIPR for $46.3 million back in 2019. Then it stacked tenant-improvement dollars into the rent base across Ohio, Michigan, and Massachusetts. Triple-net. Long-dated. Escalating 3% a year while wholesale prices went the other way. You can't refi a lease. The third caste is new money. Vireo $VREOF just landed a BMO revolver near SOFR plus 2% through its non-cannabis arm. When the 12-18% debt era ends, owners mortgage their real estate at bank rates. War chests on demand.

Why That Cash Becomes a Deal Wave

2026 has already been a roll-up year. Just the ugly kind. The repo men ran it. AYR's 60-plus Florida stores went to noteholders under $410 million of debt. Cannabist sold itself for parts. TerrAscend's Michigan hit receivership. Vireo closed five deals in six weeks and now guides to roughly 270 stores. The rent-heavy and the levered died first. That wasn't luck. That was the capital structure doing the sorting.

A positive ruling flips the tape from distressed to strategic. People close to the boardroom talks tell us the CEOs are already comparing maps. They're gaming which pairings survive state license caps. Nothing is papered. But the physics favor stock-for-stock mergers. No financing needed. And ugly leases don't block a merger. They price into the exchange ratio. The old rule still holds. Overlap plus leases kills deals. Cresco-Columbia Care died that way. A clean map plus owned real estate closes them. Trulieve-Harvest proved it.

The buyers: Green Thumb has the fortress balance sheet. Trulieve $TRLV has the only NYSE paper, with index flows behind it. Currency nobody else can print. Vireo has the cheapest capital and a deal team that closes.

The Targets, Ranked

Two names came off this board while we drafted. Vireo took Fluent and PharmaCann. The list shrinks in real time.

1. The AYR estate. Sixty-plus Florida stores plus NJ and Nevada, held by creditors. Financial owners sell into the first pop.

2. Ascend $AAWH. NJ, IL, MA, OH, PA. The textbook bolt-on for a buyer light in cap states. Points north for Trulieve.

3. Cresco $CRLBF. Best brand house in the sector. Sub-scale retail, IIPR at the table. Merge or be merged.

4. TerrAscend $TSNDF. Post-Michigan, a clean NJ, PA, and MD core at a distressed multiple.

5. Cannabist remnants. Six states under MOU with court-set comps. Priced by the pound.

6. Jushi $JUSHF. The Virginia license is the scarcest asset in cannabis. Retail legislation in Richmond is the trigger.

7. Glass House $GLAS. Nobody buys California for California. You buy the interstate option and the cheapest grow. CPG money is the wildcard bidder.

8. The private Florida license book. Capital that bet on a 2026 ballot that never made it. Stranded until 2028. Quiet deals start here.

9. MariMed $MRMD. Brands plus New England. Somebody's tuck-in.

10. Curaleaf $CURLF non-core states. The streamliner sells while it chases the uplist. Watch the divestiture tape.

The Scoreboard

Don't take our word for it. Watch four things. Who mortgages owned real estate first. That's the war chest forming. Lease-adjusted leverage versus headline net debt. That's where cheap stocks stop being cheap. Exchange ratios on the first announced merger. That's the market pricing rent stacks in public. And landlord-consent language in the merger docs. That's where the next deal lives or dies.

Schedule III doesn't just cut the tax bill. It decides whose margin they actually own. The mergers come either way. The leases set the price of admission.

One more thing, because it deserves saying plainly. The agency that spent five decades defending Schedule I keeps a marijuana fact sheet on its own site. Under overdose effects, it reads: "No deaths from overdose of marijuana have been reported." The DEA's words, not ours. This is a drug kept a tier above fentanyl since 1970, through an opioid era that buried half a million Americans. Whatever Julius recommends, don't call this ruling bold. Call it long overdue, by the DEA's own fact sheet.